Lyme disease vaccine: Valneva announces positive initial Phase 2 study results
by Press Release from Outbreak News Today on (#561KN)
Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced positive initial results for its first Phase 2 study (VLA15-201) of Lyme disease vaccine candidate VLA15. VLA15 was immunogenic across all dose groups tested. Compared to Phase 1, the higher doses used in this trial elicited higher antibody [...]
The post Lyme disease vaccine: Valneva announces positive initial Phase 2 study results appeared first on Outbreak News Today.